Erlotinib 25 MG Oral Tablet — RxCUI 603208
RxNorm drug concept · Semantic clinical drug
RxCUI 603208
Semantic clinical drug · SCD
● Current RxNorm concept 28 FDA products
52 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI603208
Official nameErlotinib 25 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aserlotinib (as erlotinib hydrochloride) 25 MG Oral Tablet
FDA products mapped28
Package NDCs mapped52
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Erlotinib: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Erlotinib works by blocking a specific protein — EGFR — that drives tumor growth. But it's most effective when your tumor has one of two particular gene changes: an exon 19 deletio...
- Why does my doctor want me tested for an EGFR mutation before starting erlotinib?
- Yes — this one really matters. You should always take erlotinib on an empty stomach, at least 1 hour before eating or 2 hours after a meal. Food can nearly double the amount of erl...
- Does it matter if I eat before taking erlotinib?
🕸️ Concept Web — How Erlotinib 25 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Erlotinib 25 MG Oral Tablet
RxCUI 603208 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Erlotinib
337525IN
-
Erlotinib
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Tarceva
337526BN
-
Tarceva
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Erlotinib Oral Tablet
477321SCDF -
Erlotinib Oral Product
1162503SCDG -
Erlotinib Pill
1162504SCDG -
Erlotinib Oral Tablet [Tarceva]
540423SBDF -
Tarceva Oral Product
1179040SBDG -
Tarceva Pill
1179041SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Erlotinib Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Erlotinib 25 MG
603207SCDC -
Erlotinib 25 MG Oral Tablet [Tarceva]
1088255SBD -
Erlotinib 25 MG [Tarceva]
1088254SBDC
-
Erlotinib 25 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Erlotinib 25 MG
SCDC · 603207 -
Erlotinib Oral Tablet
SCDF · 477321 -
Erlotinib Oral Product
SCDG · 1162503 -
Erlotinib Pill
SCDG · 1162504
Brand-Name Concepts
-
Erlotinib 25 MG Oral Tablet [Tarceva]
SBD · 1088255 -
Erlotinib 25 MG [Tarceva]
SBDC · 1088254 -
Erlotinib Oral Tablet [Tarceva]
SBDF · 540423 -
Tarceva Oral Product
SBDG · 1179040 -
Tarceva Pill
SBDG · 1179041 -
Tarceva
BN · 337526
📦 FDA Products & Package NDCs
28 products · 52 package NDCs
52 package NDCs map to RxCUI 603208 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 72205-0082-30 | 1 BOTTLE in 1 CARTON (72205-082-30) / 30 TABLET, FILM COATE... | Erlotinib Hydrochloride | Novadoz Pharmaceuticals LLC | 2021-05-11 |
| 72485-0217-30 | 1 BOTTLE in 1 BOX (72485-217-30) / 30 TABLET, FILM COATED i... | Erlotinib | Armas Pharmaceuticals Inc. | 2019-11-06 |
Observed labelers:
Zydus Lifesciences Limited (9) ·
Zydus Pharmaceuticals USA Inc. (9) ·
Alembic Pharmaceuticals Inc. (6) ·
Alembic Pharmaceuticals Limited (6) ·
Aurobindo Pharma Limited (6) ·
Sun Pharmaceutical Industries, Inc. (6)
· +4 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.